Just a few weeks ago, Cephalon looked like it was marching confidently toward the regulatory review of its drug for attention deficit hyperactivity disorder. Now, the Frazer, Pa., company appears to have developed a bit of a limp, as a panel of medical experts prepares to meet on Thursday to discuss the experimental ADHD drug Sparlon, which Cephalon is […]
Ritalin May Keep Mental Distraction at Bay
This article is no longer online